Last reviewed · How we verify
Placebo teriparatide
Placebo teriparatide is an inactive control formulation used in clinical trials to compare against active teriparatide treatment.
Placebo teriparatide is an inactive control formulation used in clinical trials to compare against active teriparatide treatment. Used for Control arm in clinical trials of teriparatide for osteoporosis.
At a glance
| Generic name | Placebo teriparatide |
|---|---|
| Also known as | Teriparatide, PTH1-34, Forteo, PTH 1-34 |
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
As a placebo, it contains no active pharmaceutical ingredient and serves as a comparator arm in randomized controlled trials of teriparatide (recombinant human parathyroid hormone 1-34). The placebo allows researchers to isolate the true therapeutic effects of teriparatide from natural disease progression and patient expectation effects.
Approved indications
- Control arm in clinical trials of teriparatide for osteoporosis
Common side effects
Key clinical trials
- Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury (PHASE2)
- Novel Combination Therapy for Osteoporosis in Men (PHASE4)
- The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA (PHASE3)
- Post-surgical Outcomes With Anabolic Agent Use in High-risk Ankle Fractures: A Pilot RCT (PHASE1, PHASE2)
- Teriparatide on Maxillary Sinus Floor Osseointegration (PHASE4)
- Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures (PHASE3)
- Teriparatide as a Chondroregenerative Therapy in OA (PHASE2)
- Fracture Recovery for Returning to Duty (Teriparatide STRONG) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo teriparatide CI brief — competitive landscape report
- Placebo teriparatide updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI